An Extension Study of ANAVEX2-73 in Patients With Mild to Moderate Alzheimer's Disease

Last updated: January 11, 2021
Sponsor: Anavex Life Sciences Corp.
Overall Status: Completed

Phase

2

Condition

Dementia

Alzheimer's Disease

Memory Loss

Treatment

N/A

Clinical Study ID

NCT02756858
ANAVEX2-73-003
  • Ages 55-85
  • All Genders

Study Summary

This open label extension study is designed to provide continued access to ANAVEX 2-73 for eligible subjects with mild to moderate Alzheimer's Disease who have previously participated in the Anavex sponsored study ANAVEX2-73-002.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Previous exposure to ANAVEX2-73 via participation in Phase 2a Study of ANAVEX2-73Adaptive-Trial-Design With Repeated Doses, MTD Finding, Pharmacodynamic andBioavailability Evaluation in Patients With Mild to Moderate Alzheimer's Disease Witha 12-Month Open Label Follow-Up Period (ANAVEX2-73-002)

Exclusion

Exclusion Criteria:

  • Have not previously participated Phase 2a Study of ANAVEX2-73 Adaptive-Trial-DesignWith Repeated Doses, MTD Finding, Pharmacodynamic and Bioavailability Evaluation inPatients With Mild to Moderate Alzheimer's Disease With a 12-Month Open LabelFollow-Up Period (ANAVEX2-73-002)

Study Design

Total Participants: 21
Study Start date:
March 01, 2016
Estimated Completion Date:
November 30, 2020

Connect with a study center

  • Austin Health - Heidelberg Repatriation Hospital

    Melbourne, Victoria 3084
    Australia

    Site Not Available

  • Caulfield Hospital

    Melbourne, Victoria 3162
    Australia

    Site Not Available

  • Melbourne Health - The Royal Melbourne Hospital

    Melbourne, Victoria 3050
    Australia

    Site Not Available

  • Nucleus Network- Centre for Clinical Studies

    Melbourne, Victoria
    Australia

    Site Not Available

  • St. Vincent's Hospital

    Melbourne, Victoria
    Australia

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.